Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Akorn Inc (AKRX)

Akorn Inc (AKRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,984
  • Shares Outstanding, K 133,152
  • Annual Sales, $ 682,430 K
  • Annual Income, $ -226,770 K
  • 60-Month Beta 1.15
  • Price/Sales 0.02
  • Price/Cash Flow 0.19
  • Price/Book N/A
Trade AKRX with:
  • Price/Earnings ttm 0.64
  • Earnings Per Share ttm 0.14
  • Most Recent Earnings 0.02 on 10/31/19
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0900 unch
on 05/29/20
0.3749 -75.99%
on 05/12/20
-0.1500 (-62.50%)
since 04/29/20
3-Month
0.0900 unch
on 05/29/20
1.3000 -93.08%
on 03/02/20
-1.0700 (-92.24%)
since 02/28/20
52-Week
0.0900 unch
on 05/29/20
5.4600 -98.35%
on 06/28/19
-4.0000 (-97.80%)
since 05/29/19

Most Recent Stories

More News
Ocular Inflammation Treatment Market Share Growth, Size Value, Trends, Rigonal outlook by 2028

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report Allergan Plc, Valeant...

AKRX : 0.0900 (-51.01%)
ALIM : 9.05 (+0.33%)
AGN : 193.02 (+0.02%)
NVS : 92.39 (-0.79%)
PFE : 39.05 (-1.41%)
VRX.TO : 30.80 (-3.33%)
Global Ocular Inflammation Treatment Market Growth, Latest Trend and Forecast Report 2021-2027 by Eon Market Research

The new release by Eon Market Research with the title , Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2021 to 2027 is intended to give insights into the current trends and...

AKRX : 0.0900 (-51.01%)
ALIM : 9.05 (+0.33%)
AGN : 193.02 (+0.02%)
NVS : 92.39 (-0.79%)
PFE : 39.05 (-1.41%)
VRX.TO : 30.80 (-3.33%)
Global Specialty Generics Market Things to Focus on to Ensure Long-term Success | Novartis,Pfizer Inc., Turing Pharmaceuticals, Teva Pharmaceutical Ltd., Mylan N.V.,Akorn, Inc., and Mallinckrodt.

Specialty Generics are the generic versions of specialty pharmaceutical products. They are cost-effective when compared with specialty pharmaceuticals. Specialty generics include biopharmaceuticals, blood...

AKRX : 0.0900 (-51.01%)
NVS : 92.39 (-0.79%)
PFE : 39.05 (-1.41%)
VRX.TO : 30.80 (-3.33%)
Specialty Generics Market Size to be Worth Around US$ 274.9 Billion by 2030

The global Specialty Generics market size is expected to be worth around US$ 274.9 billion by 2030, according to a new report by Vision Research Reports. The global Specialty Generics market size was...

AKRX : 0.0900 (-51.01%)
ENDP : 4.73 (-0.84%)
NVS : 92.39 (-0.79%)
PFE : 39.05 (-1.41%)
TEVA : 10.20 (+0.49%)
VRX.TO : 30.80 (-3.33%)
What are The Major Factors Expected to Limit The Growth Of The Ocular Inflammation Treatment Market?

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 9.05 (+0.33%)
AGN : 193.02 (+0.02%)
NVS : 92.39 (-0.79%)
PFE : 39.05 (-1.41%)
VRX.TO : 30.80 (-3.33%)
Dry Eye Syndrome Treatment Market 2021 SWOT Analysis (PDF Report) & Key Business Strategies by Leading Players |Novartis AG, Allergan, Alcon

The studies on worldwide Dry Eye Syndrome Treatment market evaluate the capabilities, organizations, infrastructure, determines measures to attain success. Due to an, the study at permits the traders to...

ABT : 110.84 (-0.11%)
AKRX : 0.0900 (-51.01%)
AGN : 193.02 (+0.02%)
NVS : 92.39 (-0.79%)
VRX.TO : 30.80 (-3.33%)
Global Bacterial Conjunctivitis Drug Market By Product Type, By Frequency, By Application, By End User, By Region, Industry Analysis and Forecast, 2021 – 2027

New York, US, The business report released by Zion Market Research on market is focused to facilitate a deep understanding of the market definition, potential, and scope. The report is curated after deep...

AKRX : 0.0900 (-51.01%)
AGN : 193.02 (+0.02%)
BAYRY : 15.1900 (-1.17%)
MRK : 75.58 (-0.80%)
NVS : 92.39 (-0.79%)
PRGO : 46.03 (-1.16%)
PFE : 39.05 (-1.41%)
SNPHF : 13.8200 (+1.02%)
TEVA : 10.20 (+0.49%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market Research Report by Trends, by Type, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 9.05 (+0.33%)
AGN : 193.02 (+0.02%)
NVS : 92.39 (-0.79%)
PFE : 39.05 (-1.41%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market Projections, SWOT Analysis, Risk Analysis, and Forecast by 2030-Market.Biz

AKRX : 0.0900 (-51.01%)
ALIM : 9.05 (+0.33%)
AGN : 193.02 (+0.02%)
NVS : 92.39 (-0.79%)
PFE : 39.05 (-1.41%)
VRX.TO : 30.80 (-3.33%)
Global Specialty Generic Drugs Market Size 2021 - Production and Consumption Professional Analysis (Impact of COVID-19)

has recently added a new report that provides forecasts and analyses of the global . The report examines market performance during the forecast period of 2021 – 2026 in terms of revenue (US$ Mn). The...

AKRX : 0.0900 (-51.01%)
ENDP : 4.73 (-0.84%)
PFE : 39.05 (-1.41%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals,...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 0.2300
1st Resistance Point 0.1600
Last Price 0.0900
1st Support Level 0.0550
2nd Support Level 0.0200
3rd Support Level N/A

See More

52-Week High 5.4600
Fibonacci 61.8% 3.4087
Fibonacci 50% 2.7750
Fibonacci 38.2% 2.1413
Last Price 0.0900
52-Week Low 0.0900

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar